z-logo
open-access-imgOpen Access
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Author(s) -
Stuart J. Connolly,
Mark Crowther,
John W. Eikelboom,
C. Michael Gibson,
John T. Curnutte,
John H. Lawrence,
Patrick Yue,
Michele Bronson,
Genmin Lu,
Pamela B. Conley,
Peter Verhamme,
Jeannot Schmidt,
Saskia Middeldorp,
Alexander T. Cohen,
Jan BeyerWestendorf,
Pierre Albaladejo,
José LópezSendón,
Andrew M. Demchuk,
Daniel J. Pallin,
Mauricio Concha,
Shelly Goodman,
Janet M. Leeds,
Sonia Souza,
Deborah Siegal,
Elena Zotova,
Brandi Meeks,
Sadia Ahmad,
Juliet Nakamya,
Truman J. Milling
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1814051
Subject(s) - medicine , liter , bolus (digestion) , rivaroxaban , hemostasis , anesthesia , surgery , gastroenterology , warfarin , atrial fibrillation
Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom